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Abstract 
Death by stroke occurs every four minutes to human beings.  Strokes cause necrosis within the 
tissue of the brain due to deprivation of oxygen.  Perfluorocarbons have the ability to transport 
oxygen to tissue and in return decrease cell death.  Dodecafluoropentane (DDFP) is a volatile 
fluorocarbon and collection in vivo can be a challenge since this compound evaporates at room 
temperature.  There is currently not an efficient collection method in vivo for compounds that are 
volatile.  Without a method to collect DDFP it is impossible to be approved for clinical use since 
exact concentrations of the drug within the body will be unknown.  The current in vitro work 
demonstrates that microdialysis can collect volatile organic compounds, isoflurane (a standard 
inhalation anesthetic) and DDFP.  Different perfusion fluids and flow rates were tested for 
optimal analyte collection through the microdialysis membrane.  Instead of utilizing an aqueous 
perfusion fluid safflower oil and air was passed through the microdialysis probe.  The perfusion 
fluid and flow rate of choice for isoflurane sampling was safflower oil at 0.5 µL/min, 
respectively.  For DDFP there was no significance in flux between flow rates and air was a more 
suitable perfusate.  Since oil was a potential candidate as a perfusion fluid through the 
microdialysis probe, the oil/air partition coefficients (KOil/Air) were calculated.  KOil/Air was 
determined because the analyte in the air phase will partition into the oil phase that is being 
perfused through the microdialysis probe.  The average calculated KOil/Air for Isoflurane and 
DDFP was 10.62 and 0.53, respectively.  These values lead to isoflurane partitioning more into 
oil vs. air and DDFP partitioning more into air vs. oil. The new analytical method described here 
shows that VOC’s can be collected with microdialysis sampling technique and thus serves as a 
starting point for in vivo collections has been found.  
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Introduction   
Significance  
Dodecaflouropentane (DDFP) has been shown to be an excellent candidate for oxygen 
transportation by decreasing the infarct volume in rabbit brain after stroke.
1, 2
  DDFP is a volatile 
organic compound (VOC) that is hydrophobic with low boiling point (bp) of 29˚C.  With such a 
low bp this compound evaporates at room temperature making it challenging to analyze.  There 
is currently not a sufficient method to collect volatile organic compounds (VOC’s) in vivo.  By 
using the microdialysis sampling technique, a real time concentration profile may be determined 
for DDFP and other VOC’s allowing them to proceed to clinical trials.  Before in vivo sampling 
can begin in vitro microdialysis experiments need to be conducted to prove that DDFP and other 
VOC’s can be collected with this microdialysis sampling setup.  
Background  
There are numerous conditions that impair oxygen transportation to tissue.  The 
deprivation of oxygen eventually leads to tissue damage and or death.  Some of these ailments 
are caused by trauma and natural diseases.  A disease that has harshly impacted the world is 
stroke.  This disease has predominantly two forms - ischemic and hemorrhagic stroke.  The 
American Heart Association (AHA) defines a hemorrhagic stroke as when a blood vessel’s 
stability diminishes and causes a fissure in the blood vessel.
3
  The AHA defines an ischemic 
stroke as a blood vessel having a blockage.
4
  This vessel blockage does not allow adequate 
provisions of blood to the brain.  The World Health Organization (WHO) reported that stroke 
and ischemic heart disease was the number one leading cause of death in women in 2011 and it 
has been ranked as the number two cause of death in the world as of 2012.
5,
 
6
   In the United 
States stroke is ranked number four in the leading causes of death.
1
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Dodecafluoropentane Properties and Benefits 
Dodecafluoropentane has the ability to transport and deliver oxygen.  
7
  This fluorocarbon is also 
hydrophobic.  This allows for the fluorocarbon to pass primarily into tissues.
7
  DDFP has an 
average half-life in humans of 2.2±1.2 minutes in blood and a 98±19% recovery at 2 hours from 
the injection into the peripheral vein.
8
  Once DDFP has been injected intravenously it is exhaled 
from the lungs.
9
  The molecule also has a linear geometry allowing it to have a higher affinity for 
O2.
10
 Another interesting characteristic of DDFP is that it can exist as an emulsion.  These 
dodecafluoropentane emulsions (DDFPe) stabilize the compound and are much smaller than 
erythrocytes.
7
 The size of these emulsions range from 250 – 300 nanometers.1  The DDFPe have 
been shown to be effective oxygen carriers with rabbit stroke models.
1, 2
  The model 
demonstrated that there was a reduction in the median infarct volume within the brain as shown 
in Figure 1.
1
  
 Stroke is not the only ailment that DDFP can aid.  DDFP has been tested for the 
radiosensitization of Morris 7777 hepatoma.  There was no significant sensitization with just 
DDFP alone but when combined with carbogen the tumor was no longer impervious to 
sensitization.
11
  DDFP has also been recognized as a relevant ultrasound contrast agent.
12
  In an 
in vitro study of DDFP as a contrast agent showed that 98±4% of the clot was almost entirely 
eradicated.
13
  In vivo studies with different thrombolysis in myocardial infarction (TIMI) flow 
grades also exhibited a considerable amount of recanalization when DDFP was combined with 
ultrasound.
13
  This fluorocarbon may also play a role in organ preservation and carbon monoxide 
poisoning in the future.
7, 14
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Fig. 1 demonstrates the infarct volume with triphenyltetrazolium chloride (TTC) staining of 
rabbit brain slices.  The control is shown on the left and the treated (DDFPe) is on the right.  The 
control shows a significant amount of tissue death (3.9%) whereas treated shows very little 
(0.86%). Springer and Molecular Neurobiology, 48, 2013, 364, Progress in Dodecafluoropentane 
Emulsion as a Neuroprotective Agent in a Rabbit Stroke Model, Woods et. al., Figure 1, 2013, is 
given to the publication in which the material was originally published, by adding; with kind 
permission from Springer Science and Business Media" 
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In order for this compound to proceed into clinical trials a real time concentration profile 
needs to be established within the brain tissue.  Current research has only allowed for recovery 
determination from intravenous blood samples and whole tissue sample analysis.  These methods 
lack the ability to produce a real time concentration profile for the brain.  A sampling technique 
that will allow for a real time concentration profile to be established within the brain is 
microdialysis sampling. Since microdialysis sampling will be utilized for collection of the 
analyte there are parameters that need consideration.  The first issue that will need to be 
addressed is the partition coefficient (K).  The analyte will partition between the matrix and the 
perfusion fluid.   To quantitatively determine the concentration of DDFP delivered to the brain 
via intravenous injection the, perfusion fluid/extracellular fluid (ECF) partition coefficients 
needs to be calculated.  Another aspect to consider when using microdialysis is the perfusion 
fluid.  The perfusion fluid or the perfusate is a fluid that is passed through the probe to collect the 
desired analyte.  The analyte will not have the same K value with different perfusion fluids and 
different ECF’s.  When choosing a perfusion fluid there must be thought based upon what tissue 
the sampling is occurring at as well as the properties of the analyte.  For in vitro work with 
DDFP different perfusion fluids (water, safflower oil, and air) were chosen solely on the analytes 
properties.   These perfusion fluids were tested to see if DDFP could be collected in dialysate.  
Water was tested and DDFP was not detected.  This was expected since this compound is 
hydrophobic.  The next perfusion fluid tested was safflower oil.  Safflower oil was tested 
because it is a lipid and DDFP is lipophilic.  The outcome was that safflower oil was able to 
collect DDFP.  The last perfusate tested was air.  Air was chosen under the assumption that 
DDFP would have a higher concentration in the gas phase.  Air also had the ability to collect 
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DDFP.  Once the perfusion fluid was chosen the partition coefficient between perfusate/air will 
be determined and the recovery of DDFP in vitro can be quantified via microdialysis. 
Microdialysis 
Microdialysis is a minimally-invasive diffusion based sampling technique that allows for 
the constant collection of unbound molecules in various matrices (Figure 2).  The ability for the 
continuous collection of a specific analyte is caused from the concentration gradient between the 
perfusate and the fluid at the sampling site.
15
  The perfusion fluid is pushed through the inlet of 
the probe by a syringe that is connected to a pump that controls varying flow rates (0.5-2.0 
µL/min)16.  Next the perfusate travels through the semi-permeable membrane of the probe.  The 
length of membrane is 4-10 mm with an outer diameter of 200-500 µm. 17  The semi-permeable 
membrane allows molecules from the fluid at the sampling site to diffuse to and from the 
perfusate.
18
 The analyte will then travel from an area of high concentration to low 
concentration.
19
 .  The semi-permeable membrane also comes with a determined molecular 
weight cutoff (MWCO) normally 20 or 100 kDa. The MWCO allows for the ability for only 
certain molecules with that set molecular weight to pass freely across the semi-permeable 
membrane.   After the molecules have traversed the membrane the perfusion fluid transports the 
analyte to a vial where the dialysate is collected.
20
  
The molecules collected from microdialysis sampling technique are most commonly 
small endogenous and hydrophilic molecules such as dopamine and glutamate.
21
 Microdialysis 
has been proven to not only collect endogenous molecules but to also collect exogenous 
molecules such as drugs that are administered into the body.
21
  Another benefit of microdialysis 
is that it can be implanted at various sites for instance, one can sample to a particular site in the 
brain or one can choose to sample in a section of subcutaneous tissue.
22
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Fig. 2 A diagram of microdialysis sampling technique for VOC’s showing the semipermeable 
membrane allowing free molecules to diffuse in and out and travel from high concentration to 
low concentration.  
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Microdialysis is a valuable sampling technique that allows for the collection of analyte at a 
particular site while the animal is awake and freely moving.
15
  
Although microdialysis excels at collecting low molecular weight hydrophilic molecules 
it is not well known for collecting VOC’s.  It has been shown that microdialysis can collect 
VOC’s but with low recoveries.23   In the Jones et al. paper, mentioned previously, the recoveries 
obtained from this method for toluene and ethanol were 1.28% and 0.054% respectively. 
23
  
Jones directly connected the inlet of a microdialysis probe to a Helium tank and the outlet of the 
probe was connected to a GC-FID (Gas Chromatography-Flame Ionization Detector) .
23
  Helium 
was Jones choice of perfusion fluid .
23
  Since the compounds for my research are both 
hydrophobic the common aqueous perfusion fluid will repel both DDFP and isoflurane and 
therefore cannot be used. Testing different perfusion fluids and different flow rates with DDFP 
and isoflurane are a necessity to obtain best recoveries and flux data (the amount of mass per unit 
area collected over time).   The flux of these molecules was obtained instead of recovery since 
different flow rates were tested.   
Figure 3 demonstrates how different perfusion fluids will affect mass transport with the specific 
VOC’s presented in this research.  Utilizing water as a perfusate, a polar compound, will cause 
non polar molecules to be repelled.   When working with hydrophobic molecules oil is an option 
because of DDFP and isoflurane are lipophilic.  When testing different perfusion fluids the 
partition coefficient will need to be calculated because there is a potential that there will be 
higher concentrations in the non-water phases as shown in Figure 4. 
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Fig. 3 Displays diffusion/mass transport of molecules with different perfusion fluids.  
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Fig. 4 When using oil as a perfusion fluid the partition coefficient could be greater than one 
causing an increase in the concentration of the analyte.  
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Partition Coefficient 
The partition coefficient is the distribution of an analyte between two immiscible phases 
as portrayed in Figure 5.  There are a variety of immiscible phases to choose from when 
determining the partition coefficient.  A few common phases are octanol and water, oil and 
water, tissue and blood, and blood and water.  The phases chosen for this research were 
safflower oil and air.  The phases were chosen because of both compounds being lipophilic and 
volatile.     This value can be established by a general partition coefficient Eq. (1).
24
 
  
  
     
     
                                      (1) 
K is the partition coefficient, Cs2 is concentration of solute in phase 2 and Cs1 represents the 
concentration of solute in phase 1. Since DDFP is an extremely volatile compound the detection 
method of choice is headspace gas chromatography with a flame ionization detector (HS-GC-
FID).
25
 Headspace sampling is a very common sampling technique for extremely volatile 
compounds and is applicable in many fields.  With headspace sampling the gas phase above the 
sample is analyzed  (Figure 6).
25
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Fig. 5 An illustration of the partition coefficient.  
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Fig. 6 A representation of headspace sampling.  A syringe is inserted into the septum of the 
headspace vial and the gas phase is pulled out and injected into the injector port of a GC.  
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When analyzing the partition coefficients of volatile compounds with (HS-GC-FID) other 
equations need to be incorporated.  In Eq. (2) below is the relationship between the partition 
coefficient and HS-GC.
24
  
 
     
  
   
                                 (2) 
 
The peak area is denoted by A which is proportional (α) to the concentration of the gas phase 
(CG), Co is for the initial concentration, and β is for the phase ratio. The phase ratio can be 
calculated from the volume of the gas phase divided by volume of the sample phase or liquid 
phase.  From this equation the partition coefficient can be solved. Now Eq. 1 can be rearranged 
to form Eq. 3 which will allow for the determination of the concentration of solute in phase 2, 
since the concentration in solute 1 is the same as CG.    
 
                                              (3) 
 
Cs represents the concentration in the sample phase.  
 The KOil/ECF of DDFP needs to be measured because there is no way to even be 
semi-quantitative when determining the concentration of the analyte in the ECF phase.  The 
KOil/Air can be calculated separately from the KECF/Air to give the final KOil/ECF.  For DDFP, no K 
values have been reported.   This value can show the distribution of DDFP throughout the body 
and it can show whether or not the molecule is lipophobic or lipophilic.
26,
 
27
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Gas Chromatography 
Gas chromatography is a technique used to separate compounds by means of an 
interaction with a stationary phase while being carried through a column by a gaseous mobile 
phase.  The sample must be volatilized before entering the column this can be done either from 
the compound already being completely volatile or by increasing the injector port temperature at 
or above the bp of the sample.
25
 If the sample is nonvolatile there are processes that the sample 
can undergo to make it volatile, such processes are derivitization or pyrolysis.
28
  Once the sample 
is injected, it will go through the column where the analytes will start to interact with the 
column’s stationary phase depending on the properties of the analytes and the column.  Some 
properties that account for the interaction with the stationary phase of the column are solubility 
and polarity. 
29
 These interactions cause a specific retention time (tR) for analytes.  The tR is the 
time the analytes spend from injection to detection.  Once the compounds leaves the column they 
are transported by the carrier gas directly to the detector.  When the analytes reach the detector a 
signal output is produced in the form of peaks.  The peaks must have good resolution.  
Resolution is the separation of peaks.
30
  A good resolution would be 1.0 and the best resolution 
would be 1.5.   Anything below 1.0 would have a poor resolution and may not be distinguishable 
from other peaks.
30
     A GC can be coupled with many detectors such as a thermal conductivity 
detector (TCD), an FID and electron capture detector (ECD).
28
  In Figure 7 is a schematic of a  
typical GC coupled with and FID.      
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Fig. 7 A GC coupled to an FID.  The sample is injected into the injector port (INJ).  Once in the 
INJ the carrier gas carries the analytes through the column where the analyte then interacts with 
the stationary phase.  Next the analyte is carried to the detector.  
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Methods 
Materials 
Perfluroro-n-pentane (DDFP), (99%, DDFP, CAS no. 678-26-2) was purchased from 
Exfluor Research Corporation, Round Rock, TX.  Isoflurane was obtained from Henry Schein 
Animal Health, Dublin, OH.  LouAna safflower oil (100%) was acquired from Ventura Foods, 
LLC Brea, Ca. Clear headspace vials (20.0 mL) and PTFE blue silicone magnetic screw caps 
(18.0 mm) were purchased from Thermo Fisher Scientific, Waltham, Massachusetts.  Gastight 
syringes (10.0 μL and 100.0 μL) purchased from Hamilton Company, Reno, Nevada.  
Microdialysis probes (CMA 20 Polyethersulfone (PES) membrane, membrane length 10 mm, 
100kDa molecular weight cut-off MWCO) purchased from CMA Microdialysis, Harvard 
Apparatus, Holliston, MA.  Syringe pumps (BASi Bee) were purchased from BASI, West 
Lafayette, IN.  
Detection of DDFP after Collection with Microdialysis  
For the creation of the DDFP samples nine 20.0 mL headspace vials were capped and then 
crimped.  The nine vials were then taken to the cold room (2.8˚C).  Once in the cold room DDFP 
was injected into the headspace vials using a 10.0 μL gas tight glass syringe through the septum. 
The first sets of triplicates were each injected with 2.5 μL of DDFP.  The second sets of 
triplicates were injected with 3.5 μL of DDFP.  The last set of triplicates was injected with 4.5 
μL of DDFP. Next a microdialysis setup was constructed for the detection of DDFP. The setup 
consisted of three pumps with three 1000.0 μL syringes as shown in Figure 8. The syringes were 
filled with the perfusion fluid (safflower oil, LouAna safflower oil (100%)  Ventura Foods, LLC 
Brea, Ca).  Three CMA 20 microdialysis probes with a molecular weight cutoff (MWCO) of 100 
kDa were used.  Each microdialysis probe was inserted into an individual headspace vial by 
17 
 
means of an introducer.  An introducer is displayed in Figure 9. After all three probes were 
inserted into the headspace vial the inlet of the microdialysis probe was connected to the needle 
of a 1.0 mL syringe with a connector.  
Next a small piece of fluorinated ethylene propylene (FEP) tubing was inserted into three 
different headspace vials by threading the tubing through the backside of a needle. The needle 
was then inserted into the septum of the headspace vials. The needle was then removed while 
leaving the FEP tubing in the septum as shown in Figure 10.   These headspace vials were used 
as the collection vials.  The FEP tubing was then connected to the outlet of the microdialysis 
probe by a connector.  Once the set up was complete the pumps were set at 2.0 μL/ minute.  Each 
sample was performed in triplicate conditions and ran for 30.0 minutes.  The samples were then 
immediately run on the HS-GC-MS (Varian 450-GC).  The column used was a Varian Factor 
Four VF-5ms capillary column with 5% phenylmethylpolysiloxane (length 30 m, 0.25 mm ID, 
and film thickness of 0.25 µm).  The detector utilized was a triple-quad mass spectrometer 
(Varian 320-MS).  The injector temperature was set to 240 °C, the column was set to 35 °C, and 
the detector temperature was set to 240 °C.  The HS-GC-MS was set to scan for a total ion 
chromatogram from 50-300 m/z with a complete run time of 3 minutes. 
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 Fig. 8 An example of an in vitro microdialysis setup. 
 
 
 
 
 
 
 
 
Connector 
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 Fig. 9 Pictured above from left to right, an introducer, a needle placed into center of introducer, 
insertion of introducer, and insertion of the microdialysis probe into the headspace vials. 
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Fig. 10 From left to right.  The FEP tubing threaded through the backside of the needle, needle 
inserted into headspace vial, and needle removed only leaving FEP tubing in the septum.  
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Isoflurane and DDFP Absorption into Cap 
Three 20.0 mL glass headspace vials were capped.  These capped headspace vials were 
then taken into the cold room and injected with 10.0 µL of isoflurane.  The cold room (2.8 ˚C) 
was used to prevent any loss of isoflurane during the transition of isoflurane to the headspace 
vial.  The headspace vials were then taken back to sit at room temperature (20- 22 ˚C) for 30 
minutes to completely volatilize.  After the compound was had visibly evaporated the first 
injection of isoflurane was made into the injector port. Gas chromatography (GC-2014, 
Shimadzu Corporation) with a flame ionization detector (FID) was used.   All the injections of 
isoflurane into the injector port of the GC were 1.0 μL manual injections. The injector 
temperature was set at 280°C, the column at 60°C, and the detector at 280°C. The column used 
was a 5% phenyl polysilphenylene-siloxane column (SGE column, 30.0 m X 0.25 mm ID-BPX5 
X 0.25  m).  Samples were analyzed every hour from hour zero (initial creation of sample) to 
six.  This same procedure was performed for DDFP.  
Separation of Isoflurane and DDFP 
Nine 20.0 mL screw cap glass headspace vials were capped. Three glass headspace vials 
were injected with 10.0 µL of DDFP with a 10.0 µL glass gas-tight syringe. Three more glass 
headspace vials were injected with 10.0 µL of isoflurane with a 10.0 µL glass gas-tight syringe. 
The last three glass headspace vials were injected with 10.0 µL of DDFP and 10.0 µL of 
isoflurane with a 10.0 µL glass gas-tight syringe. The injections were all completed in the cold 
room (2.8˚C) to prevent any loss during the transition of DDFP and isoflurane to the glass 
headspace vials.  
22 
 
For the separation of DDFP and isoflurane the same GC-FID and the same parameters 
mentioned earlier were used.  The injection volume for the two pure compounds and for the 
mixture of the compounds was 1.0 µL with a 10.0 µL glass gas-tight syringe. 
Collection of Isoflurane and DDFP with Oil or Air as a Perfusion Fluid   
A microdialysis setup was created as shown in Figure 11.  The probe was flushed with 
safflower oil at 1.0 µL/min for 1 hour.  Three 20.0 mL glass headspace vials were capped and 
25.0 µL of isoflurane or 100.0 µL of DDFP was injected into the vials with a 100.0 µL gas tight 
glass syringe in the cold room (2.8˚C).  These samples were allowed to sit at room temperature 
(20-22˚C) to completely volatilize for 30.0 minutes.  These vials were labeled “sample vials” 1, 
2, and 3.  Nine 20.0 mL glass headspace vials were capped and labeled in three sets as 
“collection vials” hr 1, hr 2 and hr 3.  An introducer was placed into one of the collection vials 
labeled hr 1.  Another introducer was also placed into sample vial 1 and immediately the 
microdialysis probe was inserted into the vial.  The outlet tubing was also quickly inserted into 
the collection vial labeled hr 1 with an introducer.  Collection vial hr 1 was changed after the 
first hour and replaced with collection vial hr 2 for the second hour.  Finally the collection vial hr 
2 was replaced with collection vial hr 3 for the third hour.  The microdialysis probe was then 
removed and placed into sample vial 2 and the collection vials followed the same procedure for 
the collection vials for sample vial 1.This experiment was repeated with flow rates of 0.5 µL/min 
and 3.0 µL/min.  All collection vials were then analyzed by the GC-FID method.  From each 
sample 1.0 μL of sample from the headspace was removed and injected into the injector port of 
the GC.  A retention time and a peak area were obtained from the GC chromatogram.  .  A 
calibration curve was constructed according to peak areas obtained.  This experiment was also 
conducted with DDFP instead of isoflurane.  This same procedure was carried out for air as a 
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perfusion fluid except for only the first 40 minutes of sampling was taken for analysis and 
different flow rates were ran.  The flow rates chosen to use for air was 10.0 µL/min and 20.0 
µL/min.  These flow rates were chosen based upon a previous experiment.  This experiment 
consisted of placing the outlet of the microdialysis probe in a 10.0 mL beaker filled with water.  
Once the outlet of the microdialysis probe was submerged in the water different flow rates were 
tested to see if air bubbles were produced.  The visible appearance of air bubbles allowed for 
confirmation that we were able to perfuse air through the microdialysis probe.  Any flow rates 
lower than 10.0 µL/min was unable to produced sufficient air bubble production.  
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Fig. 11 A microdialysis setup for the different perfusion fluids, oil or air.  
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Partition Coefficient of Isoflurane and DDFP    
Six 20.0 mLglass headspace vials were filled with 5.0 mL of safflower oil. These glass 
headspace vials were then capped. Once capped the vials were taken into the cold room and 
injected with two different concentrations (10.0 µL and 20.0 µL) of isoflurane by inserting the 
needle of a glass gas tight syringe into the septum of the vials.  These samples were then 
immediately vortexed and left to sit at room temperature for two hours.  Equilibrium was 
determined once the peak areas remained constant at hour 5.  Once equilibrium was established, 
1.0 µL of the headspace from these vials was extracted by using a 10.0 µL glass gas tight 
syringe.  This 1.0 µL headspace sample was then injected into the GC-FID.  A calibration curve 
was created according to the peak areas obtained from the samples. This same procedure was 
also conducted for DDFP.   The partition coefficient was calculated from the average peak areas 
from the triplicate samples in the first hour.  
Results and Discussion  
Detection of DDFP  
In Figure 12 the GC-MS chromatogram shows DDFP with a retention time of 1.47 
minutes with an end run time of 3.0 minutes.  The mass spectrum obtained in Figure 13 displays 
the common fragments of DDFP. The common fragments for DDFP are 69 kDa and 118 kDa. 
The 69 kDa fragment represents CF3
-
. The 118 kDa fragment represents C2F5
-
.  A cross reference 
was done with the NIST/EPA/NIH mass spectral library (2005 version) to verify that indeed this 
was DDFP. The graph shown in Figure 14 demonstrates the linear relationship between the 
changes in concentration within the vial resulting in a specific peak area vs. the concentration 
external to the probe.  With the use of GC-MS DDFP has been identified from the collection 
samples when using microdialysis sampling.  
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Fig. 12 GC-MS chromatogram of DDFP having a retention time of 1.47. 
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Fig. 13 This is an electron impact (EI) MS of DDFP with a retention time of 1.47 minutes.  This 
was determined to be DDFP because of the two fragments 69.0 and 118.9 m/z which are the two 
most common fragments for DDFP. 
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Fig. 14 Three different concentrations of DDFP were analyzed by GC-MS to determine whether 
or not collection of DDFP was possible with oil as a perfusion fluid.  The peak areas increased 
with the larger concentrations that were external to the probe. N=3  
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Isoflurane and DDFP Absorption into Cap 
From this point on all experiments were performed using a GC-FID instead of the GC-
MS mentioned previously.  The experiment with the GC-MS was not reproducible even with 
same sample injections.  This was believed to be due to the automatic injection lacking a gas 
tight syringe.  When working with VOC’s it is imperative to work with gas tight syringes to 
prevent loss of sample.  VOC’s have been known to absorb into plastics.31  To clarify whether or 
not isoflurane or DDFP were leaking out of the headspace vial or absorbing/adsorbing into the 
cap or glass of the headspace vials a time experiment was conducted.  This experiment was 
performed over a time course of six hours. At each hour the same vial was sampled.   Figure 15 
shows a plot of the output (peak area) vs. time for both solutes.   There was no difference in the 
peak area with respect to time as determined by a repeated measures ANOVA (analysis of 
variance) with a 95% confidence interval.   
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Fig. 15 represents peak area vs. time. The peak areas were obtained from a GC-FID.  Peak area 
displayed no significant change with respect to time determined by a repeated measures 
ANOVA at a 95% confidence interval between hours.  N=3   
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Separation of Isoflurane and DDFP 
The ability to clearly separate isoflurane from DDFP was accomplished by a GC-FID.  
The injector temperature was set at 280°C, the column at 60°C, and the detector at 280°C using 
the software GC solutions.  In Figure 16A, the chromatogram shows that DDFP has a retention 
time of 3.5 and in Figure 16B isoflurane has a retention time of 3.7.  In Figure 17 the two 
compounds are shown to be separated. The calculated resolution for the two compounds was 1.2. 
Since isoflurane is the most common anesthetic for animals it will be expected that isoflurane 
will be collected and detected simultaneously in vivo with DDFP.  The ability to separate these 
two compounds with good resolution allows for the proper determination of concentration of 
these two compounds and the continuation of in vivo work         
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Fig. 16 A GC chromatogram of DDFP and isoflurane A) neat DDFP with a retention time of 
3.5 B) neat isoflurane with a retention time of 3.7.  
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Fig. 17 A GC chromatogram of a mixture of isoflurane and DDFP. 
 
DDFP Isoflurane 
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The Flux of Isoflurane and DDFP with Oil as a Perfusion Fluid  
When using oil as a perfusion fluid, the flux obtained for isoflurane at 0.5 µL/min for 
hour 1 was165±10 nmol/min, hour 2 was 124±40 nmol/min, and hour 3 was 73±40 nmol/min.  
When the flow rate was switched to 1μL/min the flux for hour 1 was 38±10 nmol/min, hour 2 
was 26±3 nmol/min, and hour 3 was 16±6 nmol/min.  With a flow rate of 3.0 µL/min the flux 
was 50±10 nmol/min at hour 1, 35±10 nmol/min at hour 2 and 27±10 nmol/min at hour 3.  
(Figure 18)  It was determined that there was a significant difference with isoflurane with respect 
to time and flow rates by a two factor ANOVA at a 95% confidence interval.  The significance 
was found between the flow rates, 3.0 µL/min and 1.0 µL/min, at hour 1 and hour 2.  There was 
significance between the flow rates, 3.0 µL/min 0.5 µL/min, at hour 1 and hour 2.  This 
significance of flux between flow rates can be identified with a lower flow rate a higher 
concentration of isoflurane can be obtained.  The fact that at 3.0 µL/min is higher than 1.0 
µL/min can be explained because at higher flow rates a higher mass recovery is obtained.  There 
is also significance between hour 1 and hour 3 for flow rate of 0.5 µL/min.  This is most likely 
due to the gradual depletion of the sample from the headspace vial.    
The flux obtained for DDFP with a flowrate of 0.5 µL/min was 16±7 nmol/min for hour 
1, 16±2 nmol/min for hour 2, and 16±7 nmol/min for hour 3.  With a flowrate of 1.0µL/min the 
flux was 22±2 nmol/min, hour 2 was 26±20 nmol/min, and hour 3 was 13±9 nmol/min.  With a 
flowrate of 3.0 µL/min the flux was 14±2 nmol/min for hour 1, 21±9 nmol/min for hour 2, and 
13±3 nmol/min for hour 3.  (Figure 19)  There was no significant difference with DDFP with 
respect to time and flowrate by a two factor ANOVA at a 95% confidence interval.  These low 
fluxes could be due to the fluorinated ethylene propylene (FEP) tubing.  Organic molecules are 
notorious for absorbing into plastics.
31
 The perfusion fluid may not have been the correct option 
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for DDFP.  Another option is that this compound could be absorbing/adsorbing to the membrane 
of the microdialysis probe. 
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Fig. 18 The flux of Isoflurane at different flow rates and time.  There was a significant difference 
between hour 1 and 3 for the 0.5 μL/min flow rate.  At flow rates of 1.0 μL/min and 3.0 μL/min 
the flux was significantly different from 0.5 μL/min at hours 1 and 2.  The significance was 
determined by a two factor ANOVA at a 95% confidence interval. N=3 
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Fig. 19 The flux of DDFP at different flow rates vs time.  There was no significant difference 
with flux with respect to time and flowrate for DDFP as determined by a two factor ANOVA at a 
95% confidence interval. N=3 
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The Flux of Isoflurane and DDFP with Air as a Perfusion Fluid   
When substituting air as a perfusion fluid the flux at 10 μL/min was163±50 nmol/min 
and at 20 μL/min 353±80 nmol/min for isoflurane.  (Figure 20)  There was a significant 
difference between flow rate 10 µL/min and 20 µL/min as determined by a t-test (p<0.025) at a 
95% confidence interval.   
The flux for DDFP at 10 μL/min was 99±9 nmol/min and at 20 μL/min was 148±4 
nmol/min. (Figure 19)  There was a significant difference between  the flow rates of 10 µL/min 
and 20 µL/min as determined by a t-test (p=0.001) at a 95% confidence interval. The higher the 
flow rate the higher the flux obtained for both compounds.  This might be a factor of obtaining 
higher mass recovery at higher flow rates.      
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Fig. 20 The flux of isoflurane and DDFP with air as a perfusion fluid at different flow rates. 
There was a significant difference in flux with increased flow rates for both compounds as 
determined by t-test at a 95% confidence interval. N=3   
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Oil/Air Partition Coefficient of Isoflurane and DDFP   
Equilibrium of DDFP and isoflurane were determined before the partition coefficient was 
calculated by observing shift in peak area at Hr 1 and Hr 5.  In Figure 21 and Figure 22 the peak 
areas remain consistent for DDFP and isoflurane.  This consistency denotes that the compounds 
have reached equilibrium.  The KOil/Air of isoflurane at 25˚C was calculated to be 10.62 from the 
average peak areas from the two concentrations (16.22 mM and 32.43 mM) as shown in Table 1.  
This partition coefficient was reported in the literature value as 98. 
32
  This can most likely be 
explained by not using the same temperature as in the literature (37˚C) and also not using olive 
oil. This value still agrees that isoflurane partitions more into oil vs. air. The oil air partition 
coefficient of DDFP at 25˚C was determined to be 0.53 from the average peak areas from the 
two concentrations (11.31 mM and 22.64 mM) as shown in Table 2.  There is currently no oil/air 
partition coefficient for DDFP in the literature. This K value denotes that DDFP partitions more 
into air vs. oil.  
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Fig. 21 DDFP’s peak area remains consistent from hour 1 to hour 5 for two different 
concentrations. N=3 
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Fig. 22 Isoflurane’s peak area remains consistent from hour 1 to hour 5 for two different 
concentrations. N=3 
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Conclusion 
 VOC’s can be collected via microdialysis sampling technique in vitro.  The fluxes of 
these compounds were calculated from different flow rates.  The microdialysis setup 
needs to be optimized due to possible loss of analyte.  For instance the use of FEP tubing 
could be a cause of loss of analyte.  By replacing this tubing with a fused silica tubing 
could increase sample recovery.  Also finding a viable perfusion fluid to collect these 
VOC’s is important.  Oil seemed to be an option for isoflurane but not for DDFP.  Air 
was a better choice for DDFP hinting that DDFP would have a lower partition coefficient. 
There are many parameters that can be changed within the microdialysis setup presented 
here.  Microdialysis can collect these compounds but further investigation needs to be 
continued.  The oil/air partition coefficients for isoflurane and DDFP have been identified 
at 25˚C.   DDFP has currently no reported value for an oil/air partition coefficient.  
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